| Reliance is developing a "second-generation" two antigen subunit protein [[:COVID-19 vaccines|COVID-19 vaccine]] called [[:COVID-19 vaccines:RelCoVax]].((Phatarphekar, A., Vidyadhar Reddy, G. E. C., Gokhale, A., Karanam, G., Kuchroo, P., Shinde, K., Masand, G., Pagare, S., Khadpe, N., Pai, S. S., Vijayan, V., Ramnath, R. L., Pratap Reddy, K., Rao, P., Harinarayana Rao, S., & Ramana, V. (2022). //RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice.// Vaccine, 40(32), 4522–4530. https://doi.org/10.1016/j.vaccine.2022.06.026)) On September 21, 2021, Dr. [[:Robert Malone]] pitched RelCoVax to an online audience at the [[:Vaccines Summit-2021]].(()) | Reliance is developing a "second-generation" two antigen subunit protein [[:COVID-19 vaccines|COVID-19 vaccine]] called [[:COVID-19 vaccines:RelCoVax]].((Phatarphekar, A., Vidyadhar Reddy, G. E. C., Gokhale, A., Karanam, G., Kuchroo, P., Shinde, K., Masand, G., Pagare, S., Khadpe, N., Pai, S. S., Vijayan, V., Ramnath, R. L., Pratap Reddy, K., Rao, P., Harinarayana Rao, S., & Ramana, V. (2022). //RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice.// Vaccine, 40(32), 4522–4530. https://doi.org/10.1016/j.vaccine.2022.06.026)) On September 21, 2021, Dr. [[:Robert Malone]] pitched RelCoVax to an online audience at the [[:Vaccines Summit-2021]].((Housatonic. (2023, February 6). //(Sep 21 2021) Robert malone: “RelCovax, 2ndGen multivalent SARS-CoV-2 vaccine candidate” (Summit).// Rumble. https://web.archive.org/web/20230208073041/https://rumble.com/v28ntb2-sep-21-2021-robert-malone-relcovax-2ndgen-multivalent-sars-cov-2-vaccine-ca.html)) ((//Speakers.// Vaccines Summit-2021. Retrieved April 20, 2021, from https://web.archive.org/web/20210420005033/https://scientiameetings.com/conferences/vaccines/speakers)) |
